Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89


MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma.

Malpeli G, Barbi S, Greco C, Zupo S, Bertolaso A, Scupoli MT, Krampera M, Kamga PT, Croce CM, Scarpa A, Zamò A.

Oncotarget. 2018 Apr 13;9(28):19961-19979. doi: 10.18632/oncotarget.24987. eCollection 2018 Apr 13.


MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype.

Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, Delabie J, Jaffe ES, Fitzgibbon J, Staudt LM, Mueller-Hermelink HK, Calaminici M, Campo E, Ott G, Hernández L, Rosenwald A.

Blood. 2011 Nov 17;118(20):5550-8. doi: 10.1182/blood-2011-06-361972. Epub 2011 Sep 29.


High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma.

Saifi M, Maran A, Raynaud P, Picot MC, Quittet P, Cartron G, Rossi JF, Costes V.

Exp Ther Med. 2010 Nov;1(6):933-938. Epub 2010 Sep 1.


Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.

Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S.

Haematologica. 2008 Feb;93(2):193-200. doi: 10.3324/haematol.11702. Epub 2008 Jan 26.


Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification.

de Leval L, Harris NL, Longtine J, Ferry JA, Duncan LM.

Am J Surg Pathol. 2001 Jun;25(6):732-41.


Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.


Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Rimsza LM, Braziel RM, Hsi ED.

Ann Oncol. 2010 Jun;21(6):1196-202. doi: 10.1093/annonc/mdp460. Epub 2009 Oct 29.


Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.

Richendollar BG, Pohlman B, Elson P, Hsi ED.

Hum Pathol. 2011 Apr;42(4):552-7. doi: 10.1016/j.humpath.2010.08.015. Epub 2011 Jan 15.


Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.

Romagnoli G, Wiedermann M, Hübner F, Wenners A, Mathiak M, Röcken C, Maass N, Klapper W, Alkatout I.

Int J Mol Sci. 2017 Sep 8;18(9). pii: E1936. doi: 10.3390/ijms18091936.


MicroRNA expression profiling of Chinese follicular lymphoma by microarray: A preliminary study.

Pan Y, Guo Y, Luo Y, Li H, Xu Y.

Int Immunopharmacol. 2016 Oct;39:41-47. doi: 10.1016/j.intimp.2016.07.006. Epub 2016 Jul 10.


Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B-cell characteristics.

Takata K, Sato Y, Nakamura N, Tokunaka M, Miki Y, Yukie Kikuti Y, Igarashi K, Ito E, Harigae H, Kato S, Hayashi E, Oka T, Hoshii Y, Tari A, Okada H, Al-Kader LA, Maeda Y, Tanimoto M, Kinoshita T, Yoshino T.

Mod Pathol. 2013 Jan;26(1):22-31. doi: 10.1038/modpathol.2012.127. Epub 2012 Aug 17. Erratum in: Mod Pathol. 2013 Aug;26(8):1152. Mohamad, Abd Alkader Lamia [corrected to Al-Kader, Lamia Abd].


CD23 expression in follicular lymphoma: clinicopathologic correlations.

Olteanu H, Fenske TS, Harrington AM, Szabo A, He P, Kroft SH.

Am J Clin Pathol. 2011 Jan;135(1):46-53. doi: 10.1309/AJCP27YWLIQRAJPW.


The prevalence and function of CD4+CXCR5+Foxp3+ follicular regulatory T cells in diffuse large B cell lymphoma.

Cha Z, Gu H, Zang Y, Wang Z, Li J, Huang W, Qin A, Zhu L, Tu X, Cheng N, Song H, Qian B.

Int Immunopharmacol. 2018 Aug;61:132-139. doi: 10.1016/j.intimp.2018.05.025. Epub 2018 Jun 2.


Gene expression profiling in follicular lymphoma and its implication for clinical practice.

Janikova A, Tichy B, Supikova J, Stano-Kozubik K, Pospisilova S, Kren L, Vasova I, Salek D, Mayer J.

Leuk Lymphoma. 2011 Jan;52(1):59-68. doi: 10.3109/10428194.2010.531412. Epub 2010 Dec 6.


High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.

Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, Hamoudi R, Howat WJ, Montserrat E, Campo E.

J Clin Oncol. 2009 Mar 20;27(9):1470-6. doi: 10.1200/JCO.2008.18.0513. Epub 2009 Feb 17.


Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma.

Chang KC, Huang X, Medeiros LJ, Jones D.

J Pathol. 2003 Nov;201(3):404-12.


Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma.

Ahearne MJ, Bhuller K, Hew R, Ibrahim H, Naresh K, Wagner SD.

Virchows Arch. 2014 Sep;465(3):351-8. doi: 10.1007/s00428-014-1615-5. Epub 2014 Jul 11.


A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36.

Katzenberger T, Kalla J, Leich E, Stöcklein H, Hartmann E, Barnickel S, Wessendorf S, Ott MM, Müller-Hermelink HK, Rosenwald A, Ott G.

Blood. 2009 Jan 29;113(5):1053-61. doi: 10.1182/blood-2008-07-168682. Epub 2008 Oct 31.


The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB.

Br J Haematol. 2016 Oct;175(1):102-14. doi: 10.1111/bjh.14201. Epub 2016 Jun 24.


MicroRNA signatures in subtypes of follicular lymphoma.

Gebauer N, Gollub W, Stassek B, Bernard V, Rades D, Feller AC, Thorns C.

Anticancer Res. 2014 May;34(5):2105-11.


Supplemental Content

Support Center